Who is sponsoring NCT00755807?

NCT00755807 is sponsored by Eli Lilly and Company.

What condition does NCT00755807 study?

NCT00755807 studies Multiple Sclerosis.

What drugs are being tested in NCT00755807?

Interventions: Duloxetine Hydrochloride (HCI), Placebo.

What is the status of NCT00755807?

NCT00755807 is currently COMPLETED.

Last reviewed 2011-11-04 · How we verify

Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.

NCT00755807 Phase 3 COMPLETED Results posted

This study is designed to primarily assess the efficacy and safety of duloxetine 60-120 mg once daily (QD) compared with placebo on the reduction of pain severity in participants with central neuropathic pain due to Multiple Sclerosis.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	239
Start date	2008-10
Completion	2010-11

Conditions

Multiple Sclerosis

Interventions

Duloxetine Hydrochloride (HCI)
Placebo

Primary outcomes

Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase) — Baseline, 6 weeks
24-hour average pain severity scores recorded daily on an 11-point Likert scale, evaluated as a weekly mean, with scores ranging from 0 (no pain) to 10 (worst possible pain). Participants should complete electronic diary each day upon awakening. The 11-point Likert scale was used for assessment of 24-hour average pain and evaluated as weekly means. Scores range from 0 (no pain) to 10 (worst possible pain). The Least Squares Mean (LS Mean) Value was adjusted for investigative site and baseline severity.

Countries

United States, Belgium, Canada, Poland